KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Change in Cash (2016 - 2025)

Boston Scientific's Change in Cash history spans 17 years, with the latest figure at $671.0 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 132.83% year-over-year to $671.0 million; the TTM value through Dec 2025 reached $1.5 billion, up 442.44%, while the annual FY2025 figure was $1.5 billion, 442.44% up from the prior year.
  • Change in Cash for Q4 2025 was $671.0 million at Boston Scientific, down from $735.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.4 billion in Q1 2024 and bottomed at -$2.0 billion in Q4 2024.
  • The 5-year median for Change in Cash is $24.0 million (2021), against an average of $7.6 million.
  • The largest annual shift saw Change in Cash soared 6888.89% in 2022 before it plummeted 2554.55% in 2024.
  • A 5-year view of Change in Cash shows it stood at $9.0 million in 2021, then skyrocketed by 6888.89% to $629.0 million in 2022, then tumbled by 112.24% to -$77.0 million in 2023, then tumbled by 2554.55% to -$2.0 billion in 2024, then skyrocketed by 132.83% to $671.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Change in Cash are $671.0 million (Q4 2025), $735.0 million (Q3 2025), and -$179.0 million (Q2 2025).